Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models

Chia-Chin Wu; Licai Huang; Zhongting Zhang; Zhenlin Ju; Xingzhi Song; E Anders Kolb; Wendong Zhang; Jonathan Gill; Min Ha; Malcolm A Smith; Peter Houghton; Christopher L Morton; Raushan Kurmasheva; John Maris; Yael Mosse; Yiling Lu; Richard Gorlick; P Andrew Futreal; Hannah C Beird

doi:10.1038/s41598-024-69382-8

Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models

Sci Rep. 2024 Aug 27;14(1):19891. doi: 10.1038/s41598-024-69382-8.

Authors

Chia-Chin Wu¹, Licai Huang², Zhongting Zhang³, Zhenlin Ju⁴, Xingzhi Song¹, E Anders Kolb⁵, Wendong Zhang³, Jonathan Gill³, Min Ha^{2

6}, Malcolm A Smith⁷, Peter Houghton⁸, Christopher L Morton⁹, Raushan Kurmasheva¹⁰, John Maris¹¹, Yael Mosse¹¹, Yiling Lu¹, Richard Gorlick³, P Andrew Futreal¹, Hannah C Beird¹²

Affiliations

¹ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Pediatric Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, DE, USA.
⁶ Department of Health Informatics and Biostatistics, Yonsei University, Seoul, Korea.
⁷ Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁸ Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
⁹ Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA.
¹⁰ Greehey Children's Cancer Research Institute, San Antonio, TX, USA.
¹¹ Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹² Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].

Abstract

Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test novel therapies is especially great in this disease since it is both rare and does not respond to most therapies. To address this, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been presented previously. This study now adds whole genome sequencing and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four additional osteosarcoma models are described for use in the research community.

MeSH terms

Animals
Bone Neoplasms* / genetics
Bone Neoplasms* / pathology
Disease Models, Animal
Humans
Mice
Osteosarcoma* / genetics
Osteosarcoma* / pathology
Protein Array Analysis / methods
Transcriptome
Whole Genome Sequencing / methods
Xenograft Model Antitumor Assays*

Abstract

MeSH terms

Grants and funding